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An Evolution to a Call-and-Response MethodValentin Fuster, MD, PHDJ azz music, which resulted from a necessity todisrupt previous traditions of European classical
music to fully incorporate American culture, her-
alded in the “call and response” device, whereby 1
section of musical instruments, such as the brass
section, would play a musical phrase and then be
“answered” by another section, such as the saxo-
phones. The ﬁrst phrase is the call, the answer is
the response, giving birth to a musical conversation
that evolved into a musical revolution.
Out of necessity, translational medicine may have
taken a similar path of deviation and evolution.
Classically, there has been a linear path of trans-
lational medicine, by which basic science gets trans-
lated to the patient and then undergoes wide-scale
distribution through clinical trials, global health ini-
tiatives, and development of clinical guidelines (the
ﬁrst pathway). However, recently there has been a
distinct change to this historical model. Through
technology and global databases, we now are able to
observe how populations respond or do not respond
to medications or procedures. Equipped with these
observations from clinical trials, global health pro-
jects, and large-scale databases, researchers are now
circling back with observational information that
impacts patient care directly (the second pathway) or
indirectly through basic science (the third pathway)
(Fig. 1).
Thus, translational medicine no longer has a single
pathway. It does not mean that the historical model is
no longer relevant, but it is now bolstered by other
means of getting the best care for patients. Let me
provide 6 ongoing 2014 examples, 2 from each
pathway, that further elucidate how these 3 pathways. Wiener Cardiovascular Institute, Icahn
inai, New York, New York.are already being implemented in contemporary
medicine.
The ﬁrst pathway, from which many previous
generations of patient care arose, remains a vital part
of the scientiﬁc process. One example relates to
cholesterol-lowering therapy with statins, which may
not be achieved because of compromised adherence
to daily medication, intolerance to or side effects
from the therapy, or insufﬁcient lowering of low-
density lipoprotein cholesterol (LDL-C) levels. An
elegant basic investigation performed in a number of
laboratories has shown that proprotein convertase
subtilisin kexin 9 (PCSK9) binds the low-density
lipoprotein receptor at the surface of hepatocytes,
thereby resulting in reduced LDL-C clearance (1).
Presently, PCSK9 monoclonal antibodies that inhibit
its function on the low-density lipoprotein receptor
are being evaluated. Thus far, evolocumab (previ-
ously AMG 145) dramatically lowered LDL-C in phase
2 clinical trials when administered subcutaneously
biweekly or monthly. Similar information is evolving
in phase 3 randomized studies, whereas the FOURIER
(Further Cardiovascular Outcomes Research With
PCSK9 Inhibition in Subjects With Elevated Risk)
study, involving 22,500 patients with atherosclerotic
disease, is underway with the ambitious objective of
event reduction (2).
A second contemporary example of the ﬁrst
pathway relates to an early intervention strategy
during ST-segment elevation myocardial infarction
(STEMI) and the evaluation of b-blockers to exert a
cardioprotective capacity by decreasing reperfusion
injury. Recent data from a pig model showed that
the b1-selective blocker metoprolol was able to
markedly reduce infarct size only when administered
early and intravenously before reperfusion. The ran-
domized METOCARD-CNIC (Effect of Metoprolol
in Cardioprotection During an Acute Myocardial
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FIGURE 1 The 3 Pathways of Translational Medicine
This illustration depicts the evolutionary pathway for translational medicine, which traditionally went from basic science to global distribution,
but is now ﬁnding new methods to introduce better care for patients.
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224Infarction) study, which applied this strategy to 270
patients with anterior STEMI, Killip class #II, who
were undergoing primary percutaneous coronary
intervention, showed that metoprolol reduced infarct
size (3). This trial’s results have led to the design of
the MOVE ON trial, a large study of approximately
4,000 STEMI patients in 9 European countries, pow-
ered to detect differences in the primary composite
endpoint of cardiac death or readmission to the hos-
pital due to heart failure, for which recruitment is
planned to start in 2015.
These 2 ongoing approaches from basic/experi-
mental to clinical practice, with the proprotein PCSK9
and a b1-selective blocker, respectively, represent 2
examples of how the ﬁrst pathway will continue to be
a vital priority in the biomedical research arena.
However, the following contemporary 4 examples of
the second and third pathways corroborate that each
of these approaches are also necessary to ensure the
best care for our patients.
The present approach to the treatment of
patients with stable complex coronary artery disease
(CAD) represents a clear example of the second
pathway. In the 1980s, based on 3 major randomized
studies (CASS, VA, and European), in patients with
stable CAD who had 2 out of 3 abnormal clinical var-
iables (left ventricular dysfunction, 3-vessel disease,
or signiﬁcant ischemia), coronary artery bypass
grafting was considered to be superior to optimal
medical therapy. In the 1990s, several small studies
argued the noninferiority of percutaneous coronary
intervention over coronary artery bypass grafting. In
the 2000s, a number of seminal clinical studies
emerged that have had a signiﬁcant inﬂuence on
our understanding of complex coronary disease,
while at the same time demonstrating that effective
treatment requires an equally complex therapeuticapproach (4). As a result of these recent studies,
sophisticated treatment algorithms have arisen that
incorporate overall anatomical complexity (SYNTAX
risk score), intravascular measured presence or
absence of ischemia by the fractional ﬂow reserve
(FFR) related to each individual epicardial coronary
stenosis, and various clinical aspects including left
ventricular dysfunction, degree of global ischemia,
and comorbidities (clinical risk score). These new
algorithms are now being taken directly from obser-
vations made over the last 10 years of clinical trials
and practical experience and are processed into
guideline-recommended treatments. This demon-
strates a clear example of the second pathway.
Another example of the second pathway relates to
the high global prevalence of obesity and diabetes, as
well as the proven difﬁculties for their control
through changes in lifestyle and pharmacology; the
question has been raised about whether bariatric
surgery could play a successful role in combating
these complications. Following a few limited but
promising studies addressing this question, the
STAMPEDE randomized trial, involving 150 obese
patients with uncontrolled type 2 diabetes, showed
that intensive medical therapy plus bariatric surgery
resulted in weight reduction and glycemic control in
signiﬁcantly more patients than did medical therapy
alone (5). The beneﬁts obtained in the bariatric sur-
gery arm also extended to the other risk factors of
the metabolic syndrome. Again, this shows research
responding to the second pathway, whereby a poten-
tial solution to a global health problem can be trans-
lated directly to the patient through a commonly
accepted procedure.
In this aging population, the burden of dementia is
rising: about 25% of all people age 55 years and older
have a family history of dementia, and the lifetime
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In response to this global epidemic, researchers have
taken a third pathway through both the National
Alzheimer’s Coordinating Center database of 5,715
autopsy cases with neuropathological and cerebro-
vascular evaluation (6) and the longitudinal study of
more than 3,000 adults in 4 U.S. cities followed over
a period of 25 years (7). Based on the information
obtained from neuropathology, neurovascular im-
aging, and psychological testing, there is strong
evolving evidence of a relationship between cardio-
vascular risk factors, cerebrovascular disease with
microinfarcts, and dementia. Researchers are deliv-
ering this new knowledge, brought about by new
imaging technologies applied at autopsy and in vivo
database, back to the laboratories of basic science to
see if they can discover new treatments for this
conﬂuence of diseases.
As another example of the third pathway, we all
have become aware of the clinical and economic
implications of the global problem of nonadherence,with <50% of patients with chronic conditions, such
as CAD, adhering to their prescribed treatment.
Across all health care categories, this accounts for
about $290 billion of annual health care expenditure
in the United States. In response to this global need,
investigators and industry went back to the basic
science laboratories to create various polypills for
secondary prevention that are presently getting ready
for patient use (8).
Thus, translational medicine no longer has a
single pathway; there has been a distinct change in
this historical model. As the early jazz musicians
developed a response to each call in order to com-
plete the musical number, investigators are utilizing 3
unique pathways to respond to the evolving needs of
contemporary cardiovascular patients.
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